Abstract:Estela Noguera-Ortega 1,2 , Steven M. Albelda 1,2 1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2 Pulmonary and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Comment on: Zhang Y, Tacheva-Grigorova SK, Sutton J, et al . Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2023;29:971-85. Keywords: Small cell lung cancer (SCLC); chimeric antigen receptor T cells (CAR T cells); delta-like ligand-3 (DLL3) Submitted Jan 03, 2024. Accepted for publication Feb 19, 2024. Published online Apr 24, 2024. doi: 10.21037/tlcr-24-10 Although great successes have been achieved treating leukemias, lymphoma, and multiple myeloma using chimeric antigen receptor T (CAR T) cells, resulting in multiple regulatory agency approvals, reports showing efficacy in solid tumors are much fewer. To date, some promising results have been seen in neuroblastoma (1) and gastro intestinal (GI) tumors (2), but lung cancer, and specifically small cell lung cancer (SCLC) has not been successfully treated. This is unfortunate, as successful treatments for this deathly cancer remain very limited. There are many postulated reasons for this lack of success in solid tumor. Key limitations include: (I) lack of highly specific targets for the CAR T cells, (II) poorly functioning T cells that produce suboptimal CAR T cells, (III) poor trafficking of the CAR T cells into tumors, (IV) tumor heterogeneity, (V) poor persistence of the cells, and (VI) rapid development of CAR T cell hypofunction. SCLC presents some additional challenges as the disease is often extensive and rapidly progressive requiring rapid preparation of the CAR T cells [reviewed in (3)]. A recent paper by Zhang et al. entitled "Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer" (4) describes a sophisticated, multipronged approach for SCLC that can serve as an example for the development of CAR T cells. The authors have elected to address some of these important solid tumor CAR T cell challenges by using allogeneic T cells. Off-the-shelf CAR T cell approaches provide a ready-to-use clinical product that can be derived from cells from young healthy donors in large scale, avoiding delays, cutting costs (by eliminating the need for a personalized product for each patient) and generating a consistent, highly effective cell therapy product (5,6). However, allogenic CAR T cell products have a number of potential issues. By using T cells from a different donor to generate CAR T cells and infusing them into the cancer patient, foreign cells are being transplanted into the donor. This results in the host immune system potentially rejecting the infused product—via host versus graft (HvG) rejection, but also, since the transplanted cells are T cells, these cells can also mount an immune response against the host, resulting in graft versus host disease (GvHD) (7). Zhang and collaborators approach these two potential limitations by using a previously described gene-editing methodology—Transcriptional Activator-Like Effector Nuclease (TALEN) to knockout genes to avoid each problem. To limit GvHD, they "knock out" the T-cell receptor α constant (TRAC) locus that encodes for the T cell receptor of the infused CAR T cells making them non-reactive against the host cells (4). Of note, other investigators have successfully used this strategy, knocking out the TRAC loci and at the same time inserting the CAR into the same locus, where it results in more uniform expression and prevents tonic signaling (8). Similar approaches are currently being evaluated in clinical trials (4,7). To enhance engraftment, CAR T cell persistence, and diminish HvG rejection, this group used lymphodepletion/immunosuppression using a pan-T cell anti-CD52 antibody. However, to prevent the CAR T cells from also being depleted by the antibody, they genetically modified the T cells using TALENs to remove CD52. This strategy was found to be effective in clinical trials (9). Both of these approaches are being developed by Allogene Therapeutics for use in other CAR T cells targeting CD19, BCMA, and CD70. An alternative approach, used by others to prevent HvG rejection, has been to knock down the beta2 microglobulin gene which prevents the surface expression of human leukocyte antigen (HLA) molecules on the surface of the T cells (10). Although this prevents them from being recognized by endogenous CD8 T cells, it does make more susceptible to NK cell mediated attack (11). The main focus of the manuscript is to validate a SCLC target called delta-like ligand-3 (DLL3) and to optimize CAR T cells expressing D -Abstract Truncated-

ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors

Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment

Temporal multi-modal single-cell analyses reveal dynamic interactions of CAR-T cells with glioblastoma and targeting of antigen-negative neoplastic cells

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Small cell, big promises: targeting small cell lung cancer with CAR T cells

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors

Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers

Loss of IFNgR1 signaling glioblastoma drives resistance to CAR T cell binding avidity and cytotoxicity due to lower downstream expression of ICAM-1

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Target Selection of CAR T Cell Therapy in Accordance with the TME for Solid Tumors.

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor

Abstract LB344: A novel approach to limit off-tumor toxicity of CAR-T cells targeting solid cancers

Dual-targeting CAR-T Cells with Optimal Co-Stimulation and Metabolic Fitness Enhance Antitumor Activity and Prevent Escape in Solid Tumors

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy

Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment